EXOZ
eXoZymes, Inc.
NASDAQ · Healthcare · Biotechnology · US
$6.85
+0.74%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | (68.6K) | — | 267.4K | — | 147.8K |
| Gross Profit | 68.6K | — | (267.4K) | — | (147.8K) |
| Operating Expenses | |||||
| R&D Expense | 4.9M | 3.7M | 1.9M | 527.5K | 348.1K |
| SG&A Expense | 5.5M | 5.9M | 3.8M | 1.3M | 836.8K |
| General & Admin Expense | 4.3M | 5.9M | — | 1.3M | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 214.4K | 96.0K | — | (70.1K) | — |
| Total Operating Expenses | 10.6M | 9.7M | 5.7M | 1.8M | 1.2M |
| Cost and Expenses | 10.6M | 9.7M | 5.9M | 1.8M | 1.3M |
| Operating Income (EBIT) | (10.6M) | (9.7M) | (5.9M) | (1.8M) | (1.3M) |
| Non-Operating | |||||
| Interest Income | (155.3K) | — | 77.6K | 100.00 | 98.00 |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | (155.3K) | — | 77.6K | 100.00 | 98.00 |
| Other Non-Op Income/Expense | 262.5K | 452.5K | 70.8K | (199.9K) | 98.00 |
| Non-Operating Income (excl Interest) | 244.5K | (452.5K) | (70.8K) | 199.9K | (98.00) |
| EBT (Pre-Tax Income) | (10.3M) | (9.3M) | (5.9M) | (2.0M) | (1.3M) |
| Income Tax Expense | (105.2K) | (105.2K) | — | 42.3K | 63.6K |
| Bottom Line | |||||
| Net Income | (10.2M) | (9.2M) | (5.9M) | (2.0M) | (1.4M) |
| Earnings from Cont. Ops | (10.2M) | (9.2M) | (5.9M) | (2.0M) | (1.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (10.2M) | (9.2M) | (5.9M) | (2.0M) | (1.4M) |
| Per Share | |||||
| Basic EPS | ($1.20) | ($1.09) | ($0.72) | ($0.25) | ($0.17) |
| Diluted EPS | ($1.20) | ($1.09) | ($0.72) | ($0.25) | ($0.17) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 8.7M | 8.4M | 8.1M | 8.1M | 8.1M |
| Diluted Shares Outstanding | 8.7M | 8.4M | 8.1M | 8.1M | 8.1M |
| Profitability Metrics | |||||
| EBITDA | (10.6M) | (9.0M) | (5.6M) | (1.8M) | (1.2M) |
| D&A | 219.3K | 288.0K | 267.4K | 196.9K | 147.8K |
| EBIT | (10.8M) | (9.3M) | (5.9M) | (2.0M) | (1.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026